Back to top
more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

62.96
567,418

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?

NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Here's Why You Should Hold on to Globus Medical Stock for Now

Investors continue to be optimistic about Globus Medical (GMED) on its stellar segmental performance.

Swayta Shah headshot

Buy These 5 Stocks With Upgraded Broker Ratings for 2020

When a broker upgrades a stock, you can rely on their judgment. Nonetheless, you should also take into account few other factors to ensure steady returns.

Here's Why You Should Retain Integra LifeSciences Stock Now

Investors can hold on to Integra LifeSciences (IART) stock in their portfolio owing to solid prospects.

Insulet Rides on Innovation, Omnipod's Wider Market Appeal

The full-market commercial launch of Insulet's (PODD) Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System is encouraging.

Medtronic (MDT) Inks Deal to Focus on Value-Based Healthcare

With shared financial responsibility between ChristianaCare and Medtronic (MDT), this coordinated effort will improve patient outcomes at reduced cost.

ResMed (RMD) Hits a 52-Week High: What's Driving the Stock?

ResMed (RMD) gains from impressive performance of its SaaS business.

Cardiovascular Systems Sees Peripheral OAS Micro Crown Success

This is a major achievement for Cardiovascular Systems (CSII) toward strengthening its portfolio for the treatment of CLI.

Tandem Diabetes Gets FDA Nod for t:slim X2 Insulin Pump

The FDA nod for Tandem Diabetes' (TNDM) t:slim X2 insulin pump with Control-IQ will speed up its pump shipments within the United States and grow its clientele.

Neogen's Food Safety Business Thrives on Ergot Alkaloids Test

The newly-developed Reveal Q+ MAX test is likely to fortify Neogen's (NEOG) presence in the global food allergen testing market.

Intersect ENT (XENT) Grows on Innovation Despite Cost Woes

The latest offering in Intersect ENT's (XENT) SINUVA portfolio is specific J code - J7401.

Walgreens Extends Deal to Form GPO With Retail Giant Kroger

Per Walgreens (WBA), its alliance with Kroger will lead to supply chain efficiencies, capitalizing on their joint resources.

Here's Why You Should Hold on to Quest Diagnostics Stock Now

Investors can retain Quest Diagnostics (DGX) stock in their portfolio, thanks to solid prospects.

Here's Why You Should Add Omnicell to Your Portfolio Now

Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.

Omnicell (OMCL) Partners With Kit Check to Offer Bluesight

This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.

NUVA vs. HAE: Which Stock Should Value Investors Buy Now?

NUVA vs. HAE: Which Stock Is the Better Value Option?

Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth

Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.

Amedisys (AMED) Benefits From Home Health and Personal Care

Amedisys' (AMED) impressive performance in the newly-unveiled Personal Care segment is appreciative.

Thermo Fisher (TMO) at a 52-Week High: What's Driving It?

Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.

NuVasive Hits New 52-Week High: What's Driving the Stock?

NuVasive (NUVA) is optimistic about maintaining the momentum on several positive developments.

NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?

NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Myriad Genetics Reports Favorable Study Result on Prequel

Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.

Boston Scientific's Watchman Implant Study Results Encourage

These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.

NuVasive Advances on Global Footprint Despite Pricing Woes

Within NuVasive's (NUVA) U.S. Spinal Hardware business, a strong uptick in case volume and tangible growth in the XLIF and ALIF franchises are major upsides.

Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits

Under the contract, ArcherDX will develop IVD tests that will run on Illumina's (ILMN) NextSeq 550Dx System.